Roche sceptical about investing more in 'guided-missile' ADC cancer drugs https://ift.tt/KPd7b2s

The Swiss group's CEO declined to comment when asked about any takeover interest in ADC specialist Seagen Inc which, according to a Wall Street Journal report last week, has attracted Merck & Co and other rival drugmakers as potential suitors.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/0eOKDCR
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.